Key takeaways
Kesimpta (ofatumumab) and Briumvi (ublituximab) are both monoclonal antibody medications used to treat relapsing forms of multiple sclerosis (MS). They work by targeting immune cells that attack the protective coverings of nerve cells. However, they differ in their administration and dosing schedules. Kesimpta is given as a subcutaneous injection, starting with weekly doses for three weeks, followed by monthly maintenance doses. In contrast, Briumvi is administered as an intravenous infusion by a healthcare professional, with an initial two-dose regimen followed by maintenance doses every six months. Kesimpta can be self-administered at home after training, while Briumvi requires a clinic visit for each infusion. Both medications can increase the risk of infections, but Briumvi is more likely to cause infusion-related reactions, which may require pre-medication. Neither medication is recommended during pregnancy, and both require hepatitis B screening before starting treatment.
